Triphosphate Injection

Adult dosage

Generally, 500 mL is administered through slow intravenous drip. The infusion rate is typically more than 180 minutes for 500 mL for adults. During central venous administration, 500 mL of this medication is mixed with dextrose solutions for continuous infusion into the central vein over 24 hours. Adjustments should be made appropriately according to age, symptoms, and body weight.

This medication must be used strictly according to the doctor's instructions. It should not be used in patients with severe renal impairment, hyperazotemia, metabolic disorders of amino acids other than liver disorders, nitrogen utilization disorders, cachectic heart failure, pulmonary edema, oliguria or anuria, hypernatremia and hyperchloremia or alkalosis, AV block, and severe myasthenia. Caution is needed for patients with severe acidosis, congestive heart failure, edema due to sodium retention, hyperkalemia, and renal impairment, as there is a risk of allergic reactions or asthma attacks due to sodium bisulfite. Hypersensitivity reactions such as rashes and symptoms like nausea or vomiting, chest discomfort, palpitations, and elevated blood pressure may occur. Rapid large-dose administration may cause acidosis, and side effects such as chills, fever, headache, shortness of breath, shock, bronchospasm, and ureteral spasm have been reported. If magnesium ions are contained, peripheral vasodilation may occur, and various metabolic complications such as metabolic acidosis, hypophosphatemia, alkalosis, hyperglycemia, diabetes, dehydration, elevated liver enzymes, and electrolyte imbalances can occur. In patients with liver failure and renal failure, blood BUN levels may rise, and those with liver failure are at risk for serum amino acid imbalances and coma. Care should be taken to monitor electrolyte imbalances during large doses, and fluid overload should be avoided in patients with kidney disease, pulmonary disease, and severe heart disease. Diabetic patients should frequently monitor their blood sugar levels, and those with hyponatremia, liver and kidney function impairment should carefully manage their dosage and hydration and electrolyte status. This medication may interact with other drugs, so caution is required when used alongside tetracyclines, calcium salts, thiamine, etc. In pregnant women, safety has not been established and should only be administered if the therapeutic benefit outweighs the risks; children require lower concentrations due to immature liver function and should frequently test their blood ammonia levels. Elderly patients need careful dose adjustments and slower administration rates due to decreased physiological functions. When administering, electrolyte balance should be monitored based on the electrolyte content, and it should be slowly injected intravenously. This medication should be prepared and managed under aseptic conditions, and cloudy or discolored solutions should not be used.

Serious side effects

Severe allergic reactions accompanied by urticaria, rashes, respiratory distress, respiratory arrest, asthma attacks, pulmonary edema, shock, bronchospasm, ureteral spasm, severe edema with elevated blood pressure, liver failure and renal failure, liver abnormalities (though jaundice symptoms are not specified but include liver failure-related symptoms), confusion, headache, seizure, coma.

Mild side effects

Rarely, hypersensitivity reactions such as rashes, nausea, vomiting, chest discomfort, palpitations, tachycardia, elevated blood pressure, chills, fever, headache, peripheral vasodilation, metabolic acidosis, hypophosphatemia, alkalosis, hyperglycemia, diabetes, osmotic diuresis and dehydration, rebound hypoglycemia, elevated liver enzymes, vitamin deficiencies and excesses, electrolyte imbalances, pediatric hyperammonaemia, elevated BUN, serum amino acid imbalances, metabolic alkalosis.

This medication should be stored in a sealed container to prevent air or moisture ingress and should be kept away from direct sunlight at normal room temperature. Room temperature generally means a temperature range of 1 to 30 degrees Celsius, and it should be avoided in excessively hot or excessively cold places.

Appearance

A colorless to pale yellow transparent solution in a polypropylene aqueous injection container.

Package unit

250 milliliters / box